You are here

Article Text

Article menu
Download PDFPDF
Letter
Cyclosporine: hope for severe COVID-19?
  1. Yashdeep Singh Pathania
  1. Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
  1. Correspondence to Dr Yashdeep Singh Pathania, Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences Jodphur, Jodhpur 342005, Rajasthan, India; yashdeepsinghpathania{at}gmail.com

https://doi.org/10.1136/bmjspcare-2020-002681

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the editor,

    We are in the midst of the COVID-19 pandemic from the SARS CoV-2. This has taken at the time of writing 0.8 million lives which has put the medical fraternity under extreme challenge to find an effective treatment. Numerous promising antiviral therapies against SARS-CoV-2 are under investigation to prevent both interindividual transmission and severe disease complications. In COVID-19 mortality is thought to be related to both direct viral pathogenicity and a dysregulated inflammatory host response. Unfortunately, current treatment remains only supportive and symptomatic. An affordable drug would help resource poor countries against this challenge. Cyclosporine …

    View Full Text

    Footnotes

    • Contributors YSP prepared and finalised the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.